New hope for kidney patients: early budesonide may slow IgA nephropathy
NCT ID NCT06676007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether starting budesonide capsules early can help people with IgA nephropathy, a kidney disease. About 200 adults with recent diagnosis and high protein in urine will take the drug for 12 months. Researchers will measure changes in protein levels and kidney function to see if the treatment is safe and effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY INITIAL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Atacicept's Long-Term promise for kidney disease
- Scientists investigate mysterious loin pain in kidney disease
- New hope for kidney patients: drug aims to prevent relapse
- 800-Patient study aims to uncover best treatments for kidney disease